Urinary proteomic profiling for diagnostic bladder cancer biomarkers

Expert Review of Proteomics

Volumn 6, Issue 5, 2009, Pages 507-514

  Goodison, Steve ^a   Rosser, Charles J ^a   Urquidi, Virginia ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Biomarker; Bladder cancer detection; Molecular signature; Oncoproteomics; Urinalysis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COMPLEMENT FACTOR H RELATED 1 PROTEIN; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 8; FAS ANTIGEN; GLYCOPROTEIN; HYALURONIC ACID; HYALURONIDASE; NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 22; PROTEIN BLCA 4; PROTEOME; TUMOR MARKER; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER CYTODIAGNOSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; FUNCTIONAL PROTEOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MORBIDITY; PATIENT MONITORING; RECURRENT CANCER; REVIEW; TANDEM MASS SPECTROMETRY; URINE CYTOLOGY;

HUMANS; PROTEINURIA; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 70350433896     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.70     Document Type: Review

References (76)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83(1), 18-29 (1999).
2. Aben KK, Kiemeney LA. Epidemiology of bladder cancer. Eur. Urol. 36(6), 660-672 (1999).
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol. 164(3 Pt 1), 680-684 (2000). (Pubitemid 30637601)
4. Rife CC, Farrow GM, Utz DC. Urine cytology of transitional cell neoplasms. Urol. Clin. North Am. 6(3), 599-612 (1979).
5. Cajulis RS, Haines GK 3rd, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn. Cytopathol. 13(3), 214-223; discussion 224 (1995).
6. Hautmann S, Toma M, Lorenzo Gomez MF et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur. Urol. 46(4), 466-471 (2004). (Pubitemid 39200854)
7. Giannopoulos A, Manousakas T, Mitropoulos D et al. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 55(6), 871-875 (2000). (Pubitemid 30330790)
8. Babjuk M, Soukup V, Pesl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71(4), 718-722 (2008).
9. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J. Urol. 172(3), 1123-1126 (2004).
10. Schaub S, Wilkins J, Weiler T et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 65(1), 323-332 (2004). (Pubitemid 38037520)
11. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7(3), 230-240 (2006). •• Describes a proteomic approach from biomarker discovery to internal validation and to validation in an independent sample set. (Pubitemid 43286453)
12. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 6(20), 5615-5627 (2006). (Pubitemid 44683225)
13. Oh J, Pyo JH, Jo EH et al. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 4(11), 3485-3497 (2004). (Pubitemid 39525299)
14. Bueler MR, Wiederkehr F, Vonderschmitt DJ. Electrophoretic, chromatographic and immunological studies of human urinary proteins. Electrophoresis 16(1), 124-134 (1995).
15. Marshall T, Williams K. Two-dimensional electrophoresis of human urinary proteins following concentration by dye precipitation. Electrophoresis 17(7), 1265-1272 (1996). (Pubitemid 26247155)
16. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 62(4), 1461-1469 (2002).
17. Heine G, Raida M, Forssmann WG. Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry. J. Chromatogr. A 776(1), 117-124 (1997). (Pubitemid 27336982)
18. Wittke S, Fliser D, Haubitz M et al. Determination of peptides and proteins in human urine with capillary electrophoresismass spectrometry, a suitable tool for the establishment of new diagnostic markers. J. Chromatogr. A 1013(1-2), 173-181 (2003). (Pubitemid 37297584)
19. Pieper R, Gatlin CL, McGrath AM et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4(4), 1159-1174 (2004). (Pubitemid 38445973)
20. Sun W, Li F, Wu S et al. Human urine proteome analysis by three separation approaches. Proteomics 5(18), 4994-5001 (2005). (Pubitemid 43016918)
21. Castagna A, Cecconi D, Sennels L et al. Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 4(6), 1917-1930 (2005).
22. Tyan YC, Guo HR, Liu CY, Liao PC. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Chim. Acta. 579(2), 158-176 (2006).
23. Coon JJ, Zurbig P, Dakna M et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics Proteomics Clin. Appl. 2, 964-973 (2008).
24. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7(9), R80 (2006). (Pubitemid 44614864)
25. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol. Cell. Proteomics. 5(10), 1760-1771 (2006).
26. Gonzales PA, Pisitkun T, Hoffert JD, T et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 20(2), 363-379 (2009).
27. Yamamoto T, Langham RG, Ronco P, Knepper MA, Thongboonkerd V. Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA. Proteomics 8(11), 2156-2159 (2008). • Describes a Human Proteome Organization initiative for the study of the urine proteome. These initiatives are essential for the standardization of data across studies.
28. Vlahou A, Schanstra J, Frokiaer J et al. Establishment of a European Network for Urine and Kidney Proteomics. J. Proteomics 71(4), 490-492 (2008). • Describes a European initiative for the study of the urine proteome. These initiatives are essential for the standardization of data across studies.
29. Zhang Y, Zhang Y, Adachi J et al. MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes. Nucleic Acids Res. 35(Database issue), D771-D779 (2007). • Database that is an extension of the Max-Planck Unified database and is one of few to focus on body fluids. (Pubitemid 46056308)
30. Li SJ, Peng M, Li H et al. Sys-BodyFluid: a systematical database for human body fluid proteome research. Nucleic Acids Res. 37(Database issue), D907-D912 (2009).
31. Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics 5(4), 1140-1149 (2005). (Pubitemid 40469041)
32. Nabi G, N'Dow J, Hasan TS, Booth IR, Cash P. Proteomic analysis of urine in patients with intestinal segments transposed into the urinary tract. Proteomics 5(6), 1729-1733 (2005). (Pubitemid 40593278)
33. Thongboonkerd V, Chutipongtanate S, Kanlaya R. Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J. Proteome Res. 5(1), 183-191 (2006). (Pubitemid 43100811)
34. Getzenberg RH, Konety BR, Oeler TA et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 56(7), 1690-1694 (1996).
35. Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J. Urol. 174(1), 64-68 (2005). (Pubitemid 40825673)
36. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J. Urol. 155(6), 2113-2119 (1996). (Pubitemid 26146717)
37. Irmak S, Tilki D, Heukeshoven J et al. Stage-dependent increase of orosomucoid and zinc-a2-glycoprotein in urinary bladder cancer. Proteomics 5(16), 4296-4304 (2005). (Pubitemid 41626097)
38. Orenes-Pinero E, Corton M, Gonzalez-Peramato P et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J. Proteome Res. 6(11), 4440-4448 (2007). (Pubitemid 350158519)
39. Saito M, Kimoto M, Araki T et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur. Urol. 48(5), 865-871 (2005). (Pubitemid 41495397)
40. Vlahou A, Schellhammer PF, Mendrinos S et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158(4), 1491-1502 (2001). (Pubitemid 32281313)
41. Mueller J, von Eggeling F, Driesch D et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur. Urol. 47(6), 885-893; discussion 893-1884 (2005). (Pubitemid 40745364)
42. Holterman DA, Diaz JI, Blackmore PF et al. Overexpression of a-defensin is associated with bladder cancer invasiveness. Urol. Oncol. 24(2), 97-108 (2006).
43. Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 24(6), 959-977 (2005).
44. Ye B, Skates S, Mok SC et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12(2), 432-441 (2006). (Pubitemid 43166132)
45. Wang Y, Ao X, Vuong H et al. Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J. Proteome Res. 7(10), 4313-4325 (2008).
46. Patwa TH, Wang Y, Miller FR et al. A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics Clin. Appl. 3(1), 51-66 (2008).
47. Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S. Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics 4(5), 329-339 (2007). (Pubitemid 350067363)
48. Kreunin P, Zhao J, Rosser C et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 6(7), 2631-2639 (2007). •• Describes the enrichment and identification of the urinary glycoproteome. (Pubitemid 47122358)
49. Tian M, Cui YZ, Song GH et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8, 241 (2008).
50. Zhao J, Patwa TH, Qiu W et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J. Proteome Res. 6(5), 1864-1874 (2007). •• Describes the analysis of the subproteome of glycoproteins and how the seperated proteins can be applied to microarrays for the analysis of both protein levels and glycosylation pattern.
51. Wang L, Li F, Sun W et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol. Cell. Proteomics 5(3), 560-562 (2006).
52. Feng S, Yang N, Pennathur S, Goodison S, Lubman DM. Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem. 81(10), 3776-3783 (2009). • Describes the development of improved glycoprotein enrichment chromatography. This will enable more efficient glycoprotein analyses in minimal sample material.
53. Schiffer E, Vlahou A, Petrolekas et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res. 15(15), 4935-4943 (2009).
54. Habuchi T, Marberger M, Droller et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl. 1), 64-74 (2005). (Pubitemid 43049608)
55. Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: international Consensus Panel on bladder tumor markers. Urology 66(6 Suppl. 1), 55-63 (2005).
56. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 374(9685), 239-249 (2009).
57. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 23(1), 30-37 (2007). (Pubitemid 46017852)
58. Sun Y, Urquidi V, Goodison S. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res. Treat. DOI: 10.1007/s10549-009-0365-6 (2009) (Epub ahead of print).
59. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 69(10), 1119-1127 (2009).
60. Hijazi A, Devonec M, Bouvier R, Revillard JP. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors. J. Urol. 141(3), 522-526 (1989). (Pubitemid 19089140)
61. Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur. Urol. 51(5), 1267-1274 (2007). (Pubitemid 46436313)
62. Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J. Urol. Nephrol. 35(4), 280-282 (2001). (Pubitemid 32906848)
63. Mian C, Pycha A, Wiener H et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161(5), 1486-1489 (1999). (Pubitemid 29136194)
64. Miyanaga N, Akaza H, Tsukamoto S et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int. J. Clin. Oncol. 8(6), 369-373 (2003). (Pubitemid 38036093)
65. Shariat SF, Bolenz C, Godoy G et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J. Urol. 182(1), 78-84; discussion 84 (2009).
66. Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3), 299-305 (2006). • Discusses the utility of bedside, point-of-care urinalysis. This is a major translational goal of proteomics biomarker discovery. (Pubitemid 43112958)
67. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol. 47(6), 736-748 (2005).
68. Lokeshwar VB. Are there molecular signatures for predicting bladder cancer prognosis? J. Urol. 176(6 Pt 1), 2347-2348 (2006).
69. Svatek RS, Herman MP, Lotan Y et al. Soluble Fas - a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106(8), 1701-1707 (2006).
70. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154(6), 2706-2713 (1995).
71. Van Le TS, Miller R, Barder T et al. Highly specific urine-based marker of bladder cancer. Urology 66(6), 1256-1260 (2005). (Pubitemid 41797301)
72. Konety BR, Nguyen TS, Brenes G et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol. 164(3 Pt 1), 634-639 (2000). (Pubitemid 30637591)
73. Uhlen M, Bjorling E, Agaton C et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 4(12), 1920-1932 (2005).
74. Kersey PJ, Duarte J, Williams A et al. The International Protein Index: an integrated database for proteomics experiments. Proteomics 4(7), 1985-1988 (2004).
75. National Cancer Institute, US National Institutes of Health, Bladder Cancer Statistics 2009 www.cancer.gov/cancertopics/types/bladder
76. HUPO 2008 7th World Congress 16-20 August 2008 Amsterdam, The Netherlands www.hupo2008.nl/